Randomized placebo-controlled trial of single-dose antibiotic prophylaxis with fusidic acid in neurosurgery.
In neurosurgery, the antibiotic prophylaxis of choice has not yet been determined. The ideal drug should have an appropriate antimicrobial spectrum and favourable pharmacokinetic properties. In addition it should be nontoxic and easy to apply. We therefore conducted in 90 patients a prospective, randomized, placebo-controlled, double-blind trial in clean neurosurgery at increased risk of wound infection using a single pre-operative dose of 500 mg fusidic acid. Fusidic acid is a steroid-like antibiotic with a serum half-life of about 10 hours and excellent activity against gram-positive bacteria, including methicillin-resistant staphylococci. The neurosurgical infection rates for craniotomies, posterior fossa surgery and implantation of foreign bodies were 2.4% in the treatment group and 9.1% in the placebo group, respectively. This difference is statistically significant at a 95% confidence level.
Mindermann
T
T
Neurochirurgische Universitätsklinik, Kantonspital Basel, Switzerland.
Zimmerli
W
W
Gratzl
O
O
D000293:Adolescent; D000328:Adult; D000368:Aged; D001927:Brain Diseases / Q000601:surgery*; D003399:Craniotomy; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D013530:Surgical Wound Infection / Q000517:prevention & control*
D005672:Fusidic Acid